I am researching outside of Charles University
Tell us about yourself
What is ahead of us?
- We will ensure that your home institution is informed.
In your workplace, if you prefer. First personal contact with the CUIP analytical team.
- CUIP will contact your home institution and sign a confidentiality agreement.
- Setting up a concrete form of cooperation with your home institution.
- The CUIP team will prepare a market analysis and research of the invention itself.
- Selection and choice of how to apply the technology in the market.
- Finding a commercial partner.
- Industrial verification of the technology.
Typically a prototype.
- Commercialization itself:
licensing technology / selling technology / founding a spin-off company
Media coverage of the technology is also part of a successful technology transfer.
Together with you, we will raise the public awareness of your scientific results.
The scientist and the home institution receive shares from commercialization.
Founded in mid-2020, GeneSpector s.r.o. is the most economically successful academic spin-off in the Czech Republic. As a result, technology from the 1st Faculty of Medicine of Charles University has become available in the vast majority of medical institutions in the Czech Republic, but also abroad.
The innovative product in the form of universal sampling kits and viRNAtrap, the flagship transport liquid, has thus brought a much-needed solution to the market in the turbulent times of the pandemic. The quality of the technology is evidenced by the immediate coverage of 34% of the Czech PCR testing market and the subsequent provision of the intensively demanded comprehensive service for laboratory equipment.
CUIP established a spin-off company in record time, which enabled rapid certification and subsequent product launch, while also preparing a successful communication and marketing campaign for the product launch.
In 2018, the US company Svenox Pharmaceuticals LLC purchased an invention originating from the Faculty of Pharmacy at Charles University in Hradec Kralove through CUIP.
The invention concerned a new type of substance to be used in the treatment of tuberculosis, making it more effective, cheaper and without side effects. As part of the purchase of the invention, Svenox Pharmaceuticals LLC has committed to secure the necessary financial and time-consuming development of the final drug.
Charles University, through CUIP, as well as the authors of the invention will have a financial share in the profit if the drug is successful.
Geneea Analytics s.r.o. has been developing artificial intelligence for text processing and analysis since 2019, using technology from the Faculty of Mathematics and Physics of Charles University (MFF UK).
As a result, its software also enables robotic text generation and image matching according to the detected context. In practice, the developers cooperate with the Economia and ČTK publishing houses. With its prototype, it initially caught the attention of tech giant Google, which supported its activities with a grant.
CUIP provided a multi-license to the software tools of MFF UK used not only by Internet corporations but also, for example, by the banking sector.